MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive
disorders. The development program is based on nonclinical evidence that MW151 improves
neurocognitive outcomes in animal models of radiation-induced cognitive impairment,
Alzheimer's disease, and other central nervous system (CNS) disorders.
The present study will provide safety and pharmacokinetic (PK) information on single
ascending doses to support decisions for continued clinical development.
Phase:
Phase 1
Details
Lead Sponsor:
Linda Van Eldik
Collaborators:
Duke Clinical Research Institute ImmunoChem Therapeutics, LLC National Institute on Aging (NIA)